Table 2.

Population outcomes

	Treatment group (n = 15)	Placebo group (n = 6)	p
During ICU stay:  - Vasopressor support, (day)a  - Mechanical ventilation, (day)a  - Renal replacement therapy, (n)	0 (0, 2) 8 (5, 12) 6	0 (0, 7) 7 (0, 14) 3	0.83 0.54 1
Organ support free days (day)a	19 (12, 29)	8 (3, 11)	< 0.05
Secondary infection, (n(%))	8 (53.3%)	2 (33.3%)	0.64
Site of secondary infection (n = 10 (%)):  - Pulmonary  - Bloodstream  - Otherb	4 (40.0%) 1 (10.0%) 3 (30.0%)	1 (10.0%) 1 (10.0%) 0
Length of ICU stay, including ICU readmission (day)*	16 (9, 32)	14 (9, 19)	0.54
Antibiotic consumption at day 29 or hospital discharge, (day)a	20 (4, 29)	13 (11, 16)	< 0.05
Mortality at day 90, (n(%))	3 (20.0%)	2 (33.3%)	0.48

^aValues reported are median (interquartile range). Dead patients are counted as 0 organ support free days alive

^b Skin, intra-abdominal, osteitis